| Basics |
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.
|
| IPO Date: |
September 7, 2005 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.64B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.38 | 2.12%
|
| Avg Daily Range (30 D): |
$1.75 | 1.00%
|
| Avg Daily Range (90 D): |
$2.13 | 1.49%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.31M |
| Avg Daily Volume (30 D): |
.13M |
| Avg Daily Volume (90 D): |
.15M |
| Trade Size |
| Avg Trade Size (Sh.): |
104 |
| Avg Trade Size (Sh.) (30 D): |
27 |
| Avg Trade Size (Sh.) (90 D): |
33 |
| Institutional Trades |
| Total Inst.Trades: |
5,400 |
| Avg Inst. Trade: |
$3.11M |
| Avg Inst. Trade (30 D): |
$4.25M |
| Avg Inst. Trade (90 D): |
$3.56M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.21M |
| Avg Closing Trade (30 D): |
$5.3M |
| Avg Closing Trade (90 D): |
$4.17M |
| Avg Closing Volume: |
29.9K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-4.06
|
$.25
|
$-2.21
|
|
Diluted EPS
|
$-4.02
|
$.24
|
$-2.21
|
|
Revenue
|
$ 187.58M
|
$ 47.63M
|
$ 45.33M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -75.86M
|
$ 4.85M
|
$ -42.45M
|
|
Operating Income / Loss
|
$ -34.27M
|
$ 8.44M
|
$ -36.22M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 52.35M
|
$ 22.42M
|
$ -24.24M
|
|
PE Ratio
|
|
|
|
|
|
|
